基于咖啡酸的二叶酸减少酶抑制剂的分子建模,合成和生物评估
Renu Sehrawat1, Ritu Pasrija2, Priyanka Rathee3
1School of Medical & Allied Sciences, K. R. Mangalam University, Gurugram, 122103, Haryana, India.
BMC chemistry
|December 19, 2024
概括
新的咖啡酸衍生物被合成并测试为二叶酸减少酶 (DHFR) 抑制剂. 化合物CE11显示出强烈的抗癌活性,而CE3和CE15显示出对各种细菌具有显著的抗微生物特性.
科学领域:
- 药用化学 医学化学
- 酶学 是一种酶学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 乙基酸减少酶 (DHFR) 是叶酸代谢中的关键酶,对细胞增殖至关重要.
- DHFR是开发抗微生物和抗癌剂的验证分子标.
- 抑制DHFR会破坏DNA合成,使其成为治疗干预的关键目标.
研究的目的:
- 设计,合成和评估新的咖啡酸衍生物作为DHFR抑制剂.
- 评估这些合成化合物的抗微生物和抗癌潜力.
- 为了阐明强效衍生物与DHFR酶的分子相互作用.
主要方法:
- 咖啡酸衍生物的合成和表征.
- 在体外酶抑制试验测试以确定针对DHFR的IC50值.
- 抗微生物活性测试针对格拉姆阳性和格拉姆阴性细菌.
- 对人类癌细胞系 (例如,MCF-7) 的抗癌活性评估.
- 分子对接研究,以预测DHFR活性部位内的结合模式和相互作用.
主要成果:
- 化合物CE11表现出强烈的DHFR抑制 (IC50=0.048μM),超过了甲状腺素的强度,并显示出对MCF-7细胞的显著抗癌活性 (IC50=5.37μM).
- 与标准药物如trimethoprim和ampicillin相比,CE3和CE15化合物表现出优异的抗菌活性,可以对抗金黄色葡萄球菌,Pseudomonas aeruginosa和大肠杆菌.
- 分子对接揭示了CE11和CE3通过疏水相互作用和与关键残留物结合有效地与DHFR活性部位结合,解释了它们观察到的活动.
结论:
- 合成的咖啡酸衍生物,特别是CE11,CE3和CE15,显示出作为新型DHFR抑制剂的有前途潜力.
- 这些化合物具有显著的抗癌和广泛的抗微生物活性.
- 这些发现支持这些衍生品的发展,作为一种新的治疗癌症和传染病的治疗剂.
相关概念视频
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Molecular Models
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...


